Deals Of The Week: Will Pharmasset’s Windfall Lead To Similar Exits For Other Hepatitis C Biotechs?
Executive Summary
Almost two weeks later, people are still talking about ramifications from Gilead’s $11 billion buyout of Pharmasset, but companies such as Roche, Elan and Curis have been active deal makers in recent days.
You may also be interested in...
Curis Teams Up With LLS To Fund Early-Stage Research
Lexington, Mass-based Curis landed up to $4 million in funding from The Leukemia & Lymphoma Society to help develop its preclinical treatment for B-cell lymphoma and multiple myeloma.
Curis/Genentech Report Positive Phase II Results For Vismodegib
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.